NCT03183505 is a Phase 2 clinical trial of Anyu Peibo in Major Depressive Disorder, sponsored by Shanghai Mental Health Center.

Who is sponsoring NCT03183505?

NCT03183505 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT03183505?

Interventions in NCT03183505: Anyu Peibo, Placebo.

What condition does NCT03183505 study?

NCT03183505 studies Major Depressive Disorder.

Is NCT03183505 still recruiting?

NCT03183505 is currently completed. Last updated 23 January 2019.

Last reviewed 2019-01-23 · How we verify

NCT03183505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb

Completed Phase 2 Last updated 23 January 2019

What this trial tests

Phase 2 trial testing Anyu Peibo in Major Depressive Disorder in 172 participants. Completed in 29 November 2018.

Timeline

30 June 2017

Primary endpoint
5 October 2018

29 November 2018

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	172
Start date	30 June 2017
Primary completion	5 October 2018
Estimated completion	29 November 2018
Sites	8 locations across China

Drugs / interventions tested

Anyu Peibo — full drug profile →
Placebo

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression. And to provide some scientific evidence for protocol designing in following phase Ⅲ clinical trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
He S, Yu Y, Huang J, Yin J, et al · · 2023 · PMID 38022835 · DOI 10.1177/20451253231212342

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 23 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing